Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series.

Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, Aubier M.

Open Respir Med J. 2013;7:21-5. doi: 10.2174/1874306401307010021. Epub 2013 Feb 22.

2.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
3.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2004;(3):CD003559. Review. Update in: Cochrane Database Syst Rev. 2006;(2):CD003559.

PMID:
15266491
4.

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.

Curr Med Res Opin. 2001;17(4):233-40.

PMID:
11922396
5.

Asthma unmasked with tumor necrosis factor-α-blocking drugs.

Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S.

Chest. 2011 Oct;140(4):1068-71. doi: 10.1378/chest.10-2350.

PMID:
21972387
6.

Anti-IgE for chronic asthma in adults and children.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD003559. Review. Update in: Cochrane Database Syst Rev. 2014;1:CD003559.

PMID:
16625585
7.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

8.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
9.

Anti-IgE for chronic asthma.

Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.

Cochrane Database Syst Rev. 2003;(3):CD003559. Review. Update in: Cochrane Database Syst Rev. 2004;(3):CD003559.

PMID:
12917972
10.

[Anti-TNF therapy in treatment of luminal Crohn's disease].

Marko B, Prka L.

Acta Med Croatica. 2013 Apr;67(2):179-89. Review. Croatian.

PMID:
24471301
11.

Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.

Grossman HL, Schlender A, Alperin P, Stanley EL, Zhang J.

Curr Med Res Opin. 2010 Dec;26(12):2779-93. doi: 10.1185/03007995.2010.526101. Epub 2010 Nov 4.

PMID:
21050061
12.

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.

Kulus M, Hébert J, Garcia E, Fowler Taylor A, Fernandez Vidaurre C, Blogg M.

Curr Med Res Opin. 2010 Jun;26(6):1285-93. doi: 10.1185/03007991003771338.

PMID:
20377320
13.

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W.

Ann Intern Med. 2011 May 3;154(9):573-82. doi: 10.7326/0003-4819-154-9-201105030-00002.

14.

Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.

Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.

Pulm Pharmacol Ther. 2012 Feb;25(1):77-82. doi: 10.1016/j.pupt.2011.11.004. Epub 2011 Dec 3.

PMID:
22155001
15.

Asthma symptoms, morbidity, and antiinflammatory use in inner-city children.

Warman KL, Silver EJ, Stein RE.

Pediatrics. 2001 Aug;108(2):277-82.

PMID:
11483788
16.

Infliximab and ulcerative colitis.

Cottone M, Mocciaro F, Modesto I.

Expert Opin Biol Ther. 2006 Apr;6(4):401-8. Review.

PMID:
16548766
17.

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.

Dewilde S, Turk F, Tambour M, Sandström T.

Curr Med Res Opin. 2006 Sep;22(9):1765-76.

PMID:
16968580
18.

TNF-alpha antagonism in severe asthma?

Desai D, Brightling C.

Recent Pat Inflamm Allergy Drug Discov. 2010 Nov;4(3):193-200. Review.

PMID:
20807193
19.

Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.

Behm BW, Bickston SJ.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893. doi: 10.1002/14651858.CD006893. Review.

PMID:
18254120
20.

Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal.

Vieira T, de Oliveira JF, da Graça Castel-Branco M.

Allergol Immunopathol (Madr). 2014 Jan-Feb;42(1):3-10. doi: 10.1016/j.aller.2012.07.006. Epub 2012 Dec 17.

PMID:
23253691

Supplemental Content

Support Center